No Data
No Data
No Data
No Data
No Data
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention
Jacobio Pharmaceuticals Group Co (HKG:1167) presented the results of two preclinical evaluations of its PARP7 inhibitor JAB-26766, and its p53 Y220C reactivator JAB-30355, at the ongoing American Asso
MT NewswiresApr 9 09:27 ET
Gacos-B (01167.HK) Presents Preclinical Data for PARP7 Inhibitor JAB-26766 and P53 Activator JAB-30355 at 2024 AACR Conference
Gelonghui, April 9 | Gacos-B (01167.HK) announced that the company announced the pre-clinical evaluation results of the PARP7 inhibitor JAB-26766 and the p53 Y220C activator JAB-30355 in summary form at the 2024 American Association for Cancer Research (AACR) annual meeting to be held from April 5 to April 10, 2024. JAB-26766 is an effective orally bioavailable PARP7 inhibitor. It is more than 1800 times more selective for PARP7 than PARP2. JAB-26766 as a single drug
Gelonghui FinanceApr 9 07:31 ET
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses
Jacobio Pharmaceuticals (HKG:1167) narrowed its loss attributable to owners in 2023 to 359.1 million yuan, or 0.46 yuan per share, from an attributable loss of 371.9 million yuan, or 0.49 yuan per yea
MT NewswiresApr 1 01:32 ET
Gacos releases 2023 annual results report, core projects are about to submit new drug marketing applications
BEIJING, SHANGHAI, AND BOSTON, March 29, 2024/PRNewswire/ -- Gacos Pharmaceuticals (1167.HK) released its 2023 annual results report. During the performance period, revenue was 63.5 million yuan, R&D investment was 372 million yuan, and a capital balance of 1.2 billion yuan at the end of 2023. Gacos also announced recent business developments and expected milestones. Dr. Wang Yinxiang, Chairman and CEO of Gacos Pharmaceuticals, said, “In the past year, several Gacos projects have progressed, and the SHP2 inhibitor JAB-3312 combined with Golerese has been approved to conduct phase III registered clinical trials in China.
PR NewswireMar 28 20:52 ET
Gacos-B (01167) achieved revenue of 63.52 million yuan in 2023
Gacos-B (01167) announced results for the year ended December 31, 2023. The group recorded revenue of 6...
Zhitong FinanceMar 28 13:46 ET
加科思-B:截至2023年12月31日止年度的年度業績公告
Futu NewsMar 28 10:26 ET · Announcements
No Data
No Data